

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1634
Lane, Roger Michael et al. Examiner: Pohnert, Steven C
INTERNATIONAL APPLICATION NO: PCT/EP03/08719
FILED: August 06, 2003
U.S. APPLICATION NO: 10/523047
35 USC §371 DATE: November 08, 2005
FOR: Methods for the Treatment of Dementia Based on Apo e Genotype

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statements filed November 8, 2005, and September 13, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- ☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- ☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the

☒ Copies of the non-asterisked references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864

Date: